Moreover, MM patients harboring low expression of either ATF3 or ATF4 mRNA had less favorable outcomes in terms of PFS than those with higher levels of both ATF3 and ATF4 (median PFS: 3.2 vs 9.0 months; Figure 2b, right). The gene discussed is ATF4; the disease is Miyoshi myopathy.